The Zhitong Finance App learned that on the evening of August 30, 2024, Dongyangguang Changjiang Pharmaceutical (01558.HK) announced its interim results. As of June 30, the group had a turnover of 2,455 billion yuan, and total profit attributable to the company's equity holders was 685 million yuan. The net profit margin increased further over the same period last year. The report shows that at present, while continuously increasing brand awareness of the core product Kewei, the Group is making every effort to cultivate chronic disease lines represented by insulin and new pharmaceutical lines represented by imitavir. In the first half of the year, the Group's other business pipelines diversified and were gradually entering a harvest period, showing a rapid growth trend in performance.

The Zhitong Finance App learned that on the evening of August 30, 2024, Dongyangguang Changjiang Pharmaceutical (01558.HK) announced its interim results. As of June 30, the group had a turnover of 2,455 billion yuan, and total profit attributable to the company's equity holders was 685 million yuan. The net profit margin increased further over the same period last year. The report shows that at present, while continuously increasing brand awareness of the core product Kewei, the Group is making every effort to cultivate chronic disease lines represented by insulin and new pharmaceutical lines represented by imitavir. In the first half of the year, the Group's other business pipelines diversified and were gradually entering a harvest period, showing a rapid growth trend in performance.